Nasdaq · CIK 0001520262
ALKS Alkermes plc.
Insider trading from SEC Form 4. Last filing 32 h ago. Close $40.61 on Oct 9, 2026, +49% from the 52-week low and -26% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
10
with a Form 4 at this company
Price and insider trades, last year
Signals
Open-market buys and sells at Alkermes plc., scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 0Weak | sell10b5-1 | Parisi Samuel Joseph VP, Finance (Interim PAO) | $66k | 1,938 | -20% | +34% from low · -5% from high | |
| 9Weak | sell 210b5-1 | Parisi Samuel Joseph VP, Finance (Interim PAO) | $132k | 3,743 | -33% | +36% from low · -3% from high | |
| 0Weak | sell 210b5-1 | Parisi Samuel Joseph VP, Finance (Interim PAO) | $47k | 1,327 | -15% | +38% from low · -1% from high | |
| 33Weak | sell 210b5-1 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $12M | 349,340 | -133% | +30% from low · 0% from high | |
| 25Weak | sell10b5-1 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $3.2M | 100,918 | -69% | +24% from low · 0% from high | |
| 9Weak | sell 310b5-1 | LAURENCIN CATO T director | $86k | 2,691 | -10% | - | |
| 40Moderate | sell 310b5-1 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $2.0M | 61,151 | -56% | - | |
| 29Weak | sell 310b5-1 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $290k | 9,221 | -13% | - | |
| 32Weak | sell 310b5-1 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $442k | 14,349 | -17% | - | |
| 21Weak | sell 310b5-1 | Nichols Christian Todd SVP, Chief Commercial Officer | $152k | 5,208 | -8% | - | |
| 15Weak | sell10b5-1 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $1.8M | 58,996 | -41% | - | |
| 9Weak | sell10b5-1 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | $309k | 10,471 | -10% | - |
Congressional trades
1 trade in ALKS disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | ALKS Alkermes plc - Ordinary Shares | $15k to $50k | Jul 30, 2026 | 36 days after the trade |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | Reed Joshua SVP, Chief Financial Officer | MOption exercise Ordinary Shares | +9,164 | - | - | 9,164 | 32 h ago |
| Oct 8, 2026 | Reed Joshua SVP, Chief Financial Officer | FTax withholding Ordinary Shares | -4,069 | $40.11 | $163k | 5,095 | 32 h ago |
| Oct 8, 2026 | Reed Joshua SVP, Chief Financial Officer | MOption exercise Restricted Stock Unit Awardderivative | -9,164 | - | - | 27,492 | 32 h ago |
| Oct 7, 2026 | Whitaker Anne Clem director | AGrant or award Restricted Stock Unit Awardderivative | +7,239 | $0.00 | $0 | 7,239 | 32 h ago |
| Oct 7, 2026 | Whitaker Anne Clem director | AGrant or award Non Qualified Stock Option (Right to Buy)derivative | +17,998 | $0.00 | $0 | 17,998 | 32 h ago |
| Feb 26, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | MOption exercise Ordinary Shares10b5-1 | +2,746 | - | - | 10,463 | Feb 28, 2025 |
| Feb 26, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | MOption exercise Ordinary Shares | +8,322 | - | - | 205,063 | Feb 28, 2025 |
| Feb 26, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | MOption exercise Ordinary Shares | +5,409 | - | - | 95,277 | Feb 28, 2025 |
| Feb 26, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | MOption exercise Ordinary Shares | +6,866 | - | - | 207,304 | Feb 28, 2025 |
| Feb 26, 2025 | Brown Iain Michael SVP, Chief Financial Officer | MOption exercise Ordinary Shares | +5,617 | - | - | 150,690 | Feb 28, 2025 |
| Feb 26, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Ordinary Shares | +6,866 | - | - | 80,789 | Feb 28, 2025 |
| Feb 26, 2025 | Brown Iain Michael SVP, Chief Financial Officer | FTax withholding Ordinary Shares | -2,494 | $34.80 | $87k | 148,196 | Feb 28, 2025 |
| Feb 26, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | FTax withholding Ordinary Shares | -3,049 | $34.80 | $106k | 77,740 | Feb 28, 2025 |
| Feb 26, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | FTax withholding Ordinary Shares | -2,402 | $34.80 | $84k | 92,875 | Feb 28, 2025 |
| Feb 26, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | FTax withholding Ordinary Shares | -3,695 | $34.80 | $129k | 201,368 | Feb 28, 2025 |
| Feb 26, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | FTax withholding Ordinary Shares10b5-1 | -808 | $34.80 | $28k | 9,655 | Feb 28, 2025 |
| Feb 26, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | FTax withholding Ordinary Shares | -3,049 | $34.80 | $106k | 204,255 | Feb 28, 2025 |
| Feb 26, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | MOption exercise Restricted Stock Unit Awardderivative | -5,409 | - | - | 16,229 | Feb 28, 2025 |
| Feb 26, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | MOption exercise Restricted Stock Unit Awardderivative | -8,322 | - | - | 24,967 | Feb 28, 2025 |
| Feb 26, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | MOption exercise Restricted Stock Unit Awardderivative | -6,866 | - | - | 20,598 | Feb 28, 2025 |
| Feb 26, 2025 | Brown Iain Michael SVP, Chief Financial Officer | MOption exercise Restricted Stock Unit Awardderivative | -5,617 | - | - | 16,854 | Feb 28, 2025 |
| Feb 28, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | SOpen-market sale Ordinary Shares10b5-1 | -1,938 | $34.00 | $66k | 7,717 | Feb 28, 2025 |
| Feb 26, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Restricted Stock Unit Awardderivative | -6,866 | - | - | 20,598 | Feb 28, 2025 |
| Feb 26, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | MOption exercise Restricted Stock Unit Awardderivative10b5-1 | -2,746 | - | - | 8,240 | Feb 28, 2025 |
| Feb 22, 2025 | Brown Iain Michael SVP, Chief Financial Officer | MOption exercise Ordinary Shares | +7,109 | - | - | 144,989 | Feb 25, 2025 |
| Feb 22, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Ordinary Shares | +12,279 | - | - | 75,100 | Feb 25, 2025 |
| Feb 22, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | MOption exercise Ordinary Shares | +9,694 | - | - | 196,188 | Feb 25, 2025 |
| Feb 22, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | MOption exercise Ordinary Shares | +7,109 | - | - | 89,463 | Feb 25, 2025 |
| Feb 22, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | MOption exercise Ordinary Shares10b5-1 | +3,114 | - | - | 10,831 | Feb 25, 2025 |
| Feb 22, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | MOption exercise Ordinary Shares | +7,432 | - | - | 199,463 | Feb 25, 2025 |
| Feb 22, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | FTax withholding Ordinary Shares | -5,452 | $35.32 | $193k | 69,648 | Feb 25, 2025 |
| Feb 22, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | FTax withholding Ordinary Shares | -3,157 | $35.32 | $112k | 86,306 | Feb 25, 2025 |
| Feb 22, 2025 | Brown Iain Michael SVP, Chief Financial Officer | FTax withholding Ordinary Shares | -3,154 | $35.32 | $111k | 141,835 | Feb 25, 2025 |
| Feb 22, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | FTax withholding Ordinary Shares10b5-1 | -983 | $35.32 | $35k | 9,848 | Feb 25, 2025 |
| Feb 22, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | FTax withholding Ordinary Shares | -4,305 | $35.32 | $152k | 191,883 | Feb 25, 2025 |
| Feb 22, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | FTax withholding Ordinary Shares | -3,300 | $35.32 | $117k | 196,163 | Feb 25, 2025 |
| Feb 23, 2025 | Brown Iain Michael SVP, Chief Financial Officer | MOption exercise Ordinary Shares | +5,825 | - | - | 147,660 | Feb 25, 2025 |
| Feb 23, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | MOption exercise Ordinary Shares10b5-1 | +2,284 | - | - | 12,132 | Feb 25, 2025 |
| Feb 23, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | MOption exercise Ordinary Shares | +8,738 | - | - | 200,621 | Feb 25, 2025 |
| Feb 23, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | MOption exercise Ordinary Shares | +7,689 | - | - | 203,852 | Feb 25, 2025 |
| Feb 23, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Ordinary Shares | +7,689 | - | - | 77,337 | Feb 25, 2025 |
| Feb 23, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | MOption exercise Ordinary Shares | +6,408 | - | - | 92,714 | Feb 25, 2025 |
| Feb 23, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | FTax withholding Ordinary Shares | -3,414 | $35.32 | $121k | 200,438 | Feb 25, 2025 |
| Feb 23, 2025 | Brown Iain Michael SVP, Chief Financial Officer | FTax withholding Ordinary Shares | -2,587 | $35.32 | $91k | 145,073 | Feb 25, 2025 |
| Feb 23, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | FTax withholding Ordinary Shares10b5-1 | -672 | $35.32 | $24k | 11,460 | Feb 25, 2025 |
| Feb 23, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | FTax withholding Ordinary Shares | -3,880 | $35.32 | $137k | 196,741 | Feb 25, 2025 |
| Feb 23, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | FTax withholding Ordinary Shares | -3,414 | $35.32 | $121k | 73,923 | Feb 25, 2025 |
| Feb 23, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | FTax withholding Ordinary Shares | -2,846 | $35.32 | $101k | 89,868 | Feb 25, 2025 |
| Feb 22, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Restricted Stock Unit Awardderivative | -12,279 | - | - | 0 | Feb 25, 2025 |
| Feb 22, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | MOption exercise Restricted Stock Unit Awardderivative | -7,109 | - | - | 0 | Feb 25, 2025 |
| Feb 25, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | SOpen-market sale Ordinary Shares10b5-1 | -3,743 | $35.26 | $132k | 7,717 | Feb 25, 2025 |
| Feb 22, 2025 | Brown Iain Michael SVP, Chief Financial Officer | MOption exercise Restricted Stock Unit Awardderivative | -7,109 | - | - | 0 | Feb 25, 2025 |
| Feb 22, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | MOption exercise Restricted Stock Unit Awardderivative | -9,694 | - | - | 0 | Feb 25, 2025 |
| Feb 22, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | MOption exercise Restricted Stock Unit Awardderivative | -7,432 | - | - | 0 | Feb 25, 2025 |
| Feb 23, 2025 | Brown Iain Michael SVP, Chief Financial Officer | MOption exercise Restricted Stock Unit Awardderivative | -5,825 | - | - | 11,650 | Feb 25, 2025 |
| Feb 23, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | MOption exercise Restricted Stock Unit Awardderivative | -7,689 | - | - | 15,379 | Feb 25, 2025 |
| Feb 22, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | MOption exercise Restricted Stock Unit Awardderivative10b5-1 | -3,114 | - | - | 0 | Feb 25, 2025 |
| Feb 23, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Restricted Stock Unit Awardderivative | -7,689 | - | - | 15,379 | Feb 25, 2025 |
| Feb 23, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | MOption exercise Restricted Stock Unit Awardderivative | -8,738 | - | - | 17,476 | Feb 25, 2025 |
| Feb 23, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | MOption exercise Restricted Stock Unit Awardderivative | -6,408 | - | - | 12,815 | Feb 25, 2025 |
| Feb 23, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | MOption exercise Restricted Stock Unit Awardderivative10b5-1 | -2,284 | - | - | 4,567 | Feb 25, 2025 |
| Feb 18, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Ordinary Shares | +8,896 | - | - | 66,771 | Feb 20, 2025 |
| Feb 18, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | MOption exercise Ordinary Shares | +8,896 | - | - | 190,444 | Feb 20, 2025 |
| Feb 18, 2025 | Brown Iain Michael SVP, Chief Financial Officer | MOption exercise Ordinary Shares | +6,354 | - | - | 139,749 | Feb 20, 2025 |
| Feb 18, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | MOption exercise Ordinary Shares | +6,354 | - | - | 194,853 | Feb 20, 2025 |
| Feb 18, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | MOption exercise Ordinary Shares | +6,354 | - | - | 84,223 | Feb 20, 2025 |
| Feb 18, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | MOption exercise Ordinary Shares10b5-1 | +2,033 | - | - | 9,750 | Feb 20, 2025 |
| Feb 19, 2025 | POPS RICHARD F Director and CEO, Alkermes plc | AGrant or award Employee Stock Option (Right to Buy)derivative | +293,921 | $0.00 | $0 | 293,921 | Feb 20, 2025 |
| Feb 18, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | FTax withholding Ordinary Shares | -3,950 | $35.90 | $142k | 62,821 | Feb 20, 2025 |
| Feb 18, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | FTax withholding Ordinary Shares | -3,950 | $35.90 | $142k | 186,494 | Feb 20, 2025 |
| Feb 18, 2025 | Brown Iain Michael SVP, Chief Financial Officer | FTax withholding Ordinary Shares | -1,869 | $35.90 | $67k | 137,880 | Feb 20, 2025 |
| Feb 18, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | FTax withholding Ordinary Shares | -2,822 | $35.90 | $101k | 192,031 | Feb 20, 2025 |
| Feb 18, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | FTax withholding Ordinary Shares | -1,869 | $35.90 | $67k | 82,354 | Feb 20, 2025 |
| Feb 18, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | FTax withholding Ordinary Shares10b5-1 | -706 | $35.90 | $25k | 9,044 | Feb 20, 2025 |
| Feb 18, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Restricted Stock Unit Awardderivative | -8,896 | - | - | 8,897 | Feb 20, 2025 |
| Feb 18, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | MOption exercise Restricted Stock Unit Awardderivative | -8,896 | - | - | 8,897 | Feb 20, 2025 |
| Feb 18, 2025 | Brown Iain Michael SVP, Chief Financial Officer | MOption exercise Restricted Stock Unit Awardderivative | -6,354 | - | - | 6,355 | Feb 20, 2025 |
| Feb 18, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | MOption exercise Restricted Stock Unit Awardderivative | -6,354 | - | - | 6,355 | Feb 20, 2025 |
| Feb 18, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | MOption exercise Restricted Stock Unit Awardderivative | -6,354 | - | - | 6,355 | Feb 20, 2025 |
| Feb 20, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | SOpen-market sale Ordinary Shares10b5-1 | -1,327 | $35.69 | $47k | 7,717 | Feb 20, 2025 |
| Feb 19, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +63,991 | $0.00 | $0 | 63,991 | Feb 20, 2025 |
| Feb 19, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +77,565 | $0.00 | $0 | 77,565 | Feb 20, 2025 |
| Feb 19, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative | +63,991 | $0.00 | $0 | 63,991 | Feb 20, 2025 |
| Feb 19, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +50,417 | $0.00 | $0 | 50,417 | Feb 20, 2025 |
| Feb 18, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | MOption exercise Restricted Stock Unit Awardderivative10b5-1 | -2,033 | - | - | 2,034 | Feb 20, 2025 |
| Feb 19, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | AGrant or award Restricted Stock Unit Awardderivative | +30,692 | $0.00 | $0 | 30,692 | Feb 20, 2025 |
| Feb 19, 2025 | Jackson Blair Curtis EVP, Chief Operating Officer | AGrant or award Restricted Stock Unit Awardderivative | +37,203 | $0.00 | $0 | 37,203 | Feb 20, 2025 |
| Feb 19, 2025 | Gaffin David Joseph EVP, CLO, Alkermes, Inc. | AGrant or award Restricted Stock Unit Awardderivative | +30,692 | $0.00 | $0 | 30,692 | Feb 20, 2025 |
| Feb 19, 2025 | Nichols Christian Todd SVP, Chief Commercial Officer | AGrant or award Restricted Stock Unit Awardderivative | +24,182 | $0.00 | $0 | 24,182 | Feb 20, 2025 |
| Feb 19, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | AGrant or award Employee Stock Option (Right to Buy)derivative10b5-1 | +12,287 | $0.00 | $0 | 12,287 | Feb 20, 2025 |
| Feb 19, 2025 | Parisi Samuel Joseph VP, Finance (Interim PAO) | AGrant or award Restricted Stock Unit Awardderivative10b5-1 | +11,965 | $0.00 | $0 | 11,965 | Feb 20, 2025 |
| Feb 12, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Ordinary Shares10b5-1 | +87,566 | $20.03 | $1.8M | 151,166 | Feb 14, 2025 |
| Feb 12, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Ordinary Shares10b5-1 | +111,630 | $19.34 | $2.2M | 262,796 | Feb 14, 2025 |
| Feb 12, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -171,813 | $32.69 | $5.6M | 90,983 | Feb 14, 2025 |
| Feb 12, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -33,108 | $33.27 | $1.1M | 57,875 | Feb 14, 2025 |
| Feb 13, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Ordinary Shares10b5-1 | +108,833 | $31.93 | $3.5M | 166,708 | Feb 14, 2025 |
| Feb 13, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Ordinary Shares10b5-1 | +35,586 | $24.59 | $875k | 202,294 | Feb 14, 2025 |
| Feb 13, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -35,586 | $34.02 | $1.2M | 166,708 | Feb 14, 2025 |
| Feb 13, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | SOpen-market sale Ordinary Shares10b5-1 | -108,833 | $36.02 | $3.9M | 57,875 | Feb 14, 2025 |
| Feb 12, 2025 | Hopkinson Craig C. EVP R&D, Chief Medical Officer | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -87,566 | $0.00 | $0 | 0 | Feb 14, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Brown Iain MichaelSVP, Chief Financial Officer
- Gaffin David JosephEVP, CLO, Alkermes, Inc.
- Hopkinson Craig C.EVP R&D, Chief Medical Officer
- Jackson Blair CurtisEVP, Chief Operating Officer
- LAURENCIN CATO Tdirector
- Nichols Christian ToddSVP, Chief Commercial Officer
- POPS RICHARD FDirector and CEO, Alkermes plc
- Parisi Samuel JosephVP, Finance (Interim PAO)
- Reed JoshuaSVP, Chief Financial Officer
- Whitaker Anne Clemdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.